Publication:
Initial Phase 2 Results of Ibrutinib Combined with Bortezomib/Dexamethasone in Previously Treated Patients with Multiple Myeloma

Simple item page
dc.contributor.authorHajek, R.
dc.contributor.authorPour, L.
dc.contributor.authorSpicka, I.
dc.contributor.authorOzcan, M.
dc.contributor.authorMaisnar, V.
dc.contributor.authorTurgut, M.
dc.contributor.authorOriol, A.
dc.contributor.authorIDMaisnar, Vladimir/0000-0003-1738-4920
dc.date.accessioned2020-06-21T13:19:13Z
dc.date.available2020-06-21T13:19:13Z
dc.date.issued2017
dc.departmentOMÜen_US
dc.department-temp[Hajek, R.] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic -- [Hajek, R.] Univ Ostrava, Fac Med, Ostrava, Czech Republic -- [Pour, L.] Univ Hosp Brno, Brno, Czech Republic -- [Spicka, I.] Charles Univ Prague, Clin Chem, Hematol, Prague, Czech Republic -- [Ozcan, M.] Ankara Univ, Sch Med, Dept Internal Med Sci, Ankara, Turkey -- [Maisnar, V.] Charles Univ Hosp, Dept Med Hematol 4, Hradec Kralove, Czech Republic -- [Turgut, M.] Ondokuz Mayis Univ, Fac Med, Dept Hematol, Samsun, Turkeyen_US
dc.description22nd Congress of the European-Hematology-Association -- JUN 22-25, 2017 -- Madrid, SPAINen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Hematol Assocen_US
dc.identifier.endpage267en_US
dc.identifier.issn0390-6078
dc.identifier.startpage267en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12399
dc.identifier.volume102en_US
dc.identifier.wosWOS:000404127002163
dc.language.isoenen_US
dc.publisherFerrata Storti Foundationen_US
dc.relation.journalHaematologicaen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleInitial Phase 2 Results of Ibrutinib Combined with Bortezomib/Dexamethasone in Previously Treated Patients with Multiple Myelomaen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu